GlassScriptPhysician profile
Rosa Bellota
NPI 1811280183
$1,293.90
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $293 · 2021: $28.00 · 2022: $125 · 2023: $20.88 · 2024: $76.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $227.30 | 2019-2020 | |
| Abbvie INC. | $165.37 | 2022-2024 | |
| Shire North American Group INC | $155.32 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $142.49 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $122.66 | 2019-2020 | |
| Eisai INC. | $61.16 | 2020 | |
| Lundbeck LLC | $57.96 | 2019-2023 | Rexulti |
| Brainsway USA INC | $53.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.89 | 2019-2020 | |
| Neos Therapeutics, LP | $45.63 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.25 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $36.86 | 2020 | |
| Arbor Pharmaceuticals, INC. | $31.20 | 2019 | |
| Neurocrine Biosciences, INC. | $29.58 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $28.85 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $17.77 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.02 | 2019 | |
| Adlon Therapeutics L.P. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Bellota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.